RE:RE: raised the bar.
hey murky.......don't come yer bun's because ispen's aboard......they ain't fussy On April 18, 2011 - Active Biotech and Ipsen entered into a broad partnership to co-develop and commercialize Active Biotechs investigational compound Tasquinimod. Under the terms of the agreement, Active Biotech granted Ipsen exclusive rights to commercialize tasquinimod worldwide, except for North and South America and Japan where Active Biotech retains all commercial and marketing rights. Both companies will co-develop tasquinimod for the treatment of castrate-resistant prostate cancer, with the possibility to develop tasquinimod in other cancer indications. - See more at: https://www.activebiotech.com/partnerships#sthash.QODUdTSo.dpuf